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The majority of human  lymphoid neoplasms are readily assigned  to either a  B  or 
T  cell lineage  (1).  Many of the problems that arise in the attempt  to categorize the 
remaining  tumors reflect insufficient  reactivity of the tumor cells with  the available 
B  and  T  cell  reagents.  However,  several  laboratories  (2-10)  have  reported  patients 
whose  neoplastic  lymphoeytes simulataneously  exhibit  B  and  T  cell surface charac- 
teristics.  This  unexpected  finding  was  initially  attributed  to  anti-sheep  erythrocyte 
activity of the surface  immunoglobulin  (2)  rather  than  to the  presence  of IgM and 
sheep  cell  receptor  on  the  surface  of the  same cell.  The  availability  of monoclonal 
anti-T cell  antibodies  (11,  12)  permits the  further  analysis of these unusual  tumors. 
We  report  five cases  of lymphoid  neoplasms  in  which  cells  with  surface-associated 
IgM also reacted with a  panel of monoclonal  anti-T cell antibodies. 
Materials  and  Methods 
The patients  reported  herein  were encountered  in a  systematic study of all patients with 
lymphoproliferative disease, whose neoplastic cells were examined in suspension by conventional 
surface marker techniques and with a panel of monoclonal T  cell antibodies. The diagnosis of 
non-Hodgkin's lymphoma was made in  the pathology department  and  subclassified  by the 
Rappaport system (13). The diagnosis of chronic lymphosarcoma cell leukemia in case 2 was 
based on a preponderance of peripheral lymphocytes with clefted nuclei (14). 
T  cell surface antigens were identified with nonfluoresceinated mouse hybridoma antibodies 
kindly supplied  by P.  C.  Kung and  G. Goldstein  of Ortho  Pharmaceutical  Corp.,  Raritan, 
N. J.  (11,  12)  and  a  fluoresceinated  F(ab')2 fraction  of a  goat  anti-mouse gamma globulin 
antiserum  (N. L. Cappel Laboratories Inc., Cochranville,  Pa.), using a  Zeiss ultraviolet light 
microscope (Carl Zeiss,  Inc., New York) (15). Cell surface immunoglobulin was detected with 
fluorescein-conjugated antiserums specific for the human IgG and IgM heavy chains and for 
the K and ?~ light chains  (Meloy Laboratories Inc., Springfield, Va.)  (16).  The percentage of 
bright-staining  cells was determined  by interposing  a  10%  transmitting  filter in  the optical 
system  (16).  The  fluorescence  microscope was  also used  to evaluate thymus-related  surface 
antigens  detected  by a  previously described  rabbit  antiserum  to  human  fetal  thymus  (16). 
Mononuclear cells that formed spontaneous rosettes with sheep erythrocytes (E-rosettes)  (16), 
bore receptors for the Fc portion of immunoglobulin (IgGOx rosettes) (17), or bore receptors for 
complement (IgMEAC rosettes) (18) were enumerated as previously described. 
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Results 
Surface immunoglobulin of one heavy (IgM) and one light (K) chain type was seen 
on  the  neoplastic lymphocytes from each patient  (Table I).  Furthermore, a  major 
fraction of the cells stained  brightly with  the  fluorescein-conjugated anti-immuno- 
globulin antisera. In case 1, lymph node cells were incubated with sheep erythrocytes 
and  the rosettes isolated on a  Ficoll-Hypaque gradient  (16).  Of the lymphoid cells 
recovered, 93 and 91%, respectively, were stained by anti-/t and anti-K antiserums. 
In case  1,  47% of the cells formed spontaneous rosettes with sheep erythrocytes, 
whereas in case 2, an average of 71% of cells were E-rosette positive. In cases 3, 4, and 
5, <25% of cells formed E-rosettes. Spontaneous rosettes were not formed with sheep 
erythroeytes after incubation at 37°C without subsequent 4°C incubation. Comple- 
ment receptors were detected on most of the neoplastic cells in cases 3 and 4, and on 
many cells in cases 2 and 5. The Fc receptor (IgGOx rosettes) was found on 10-29% 
of blood or lymph node mononuclear cells from the last four cases. Heterologous anti- 
thymocyte antiserum reacted with the lymphoma cells of all four patients tested. 
With the exception of case 5, the majority of surface IgM-positive cells in each case 
reacted with OKT11, a monoclonal antibody directed against the sheep cell receptor 
(12).  Furthermore, in all but case 2, surface Ig-positive cells reacted with OKT3, a 
monoclonal antibody that identified a marker on mature T  cells (11-13). The surface 
IgM-positive cells in cases 1, 4, and 5 also reacted with OKT8, a monoclonal antibody 
that  detects the cytotoxic/suppressor subset  of T  lymphocytes (11-13), whereas the 
lymphocytes from case 3 reacted with OKT4, which detects the inducer/helper T  cell 
subset (11-13). Finally, the majority of cells in all five neoplasms were positive for the 
Ia-like antigen that is found on most B lymphocytes, monocytes, macrophages, and 
activated T  cells (19). 
The  dual  marker  cases  were  restricted  to  non-Hodgkin's  lymphomas  of follicle 
center cell lineage.  Thus,  dual  marker  cases were not  detected among  17  cases of 
chronic lymphocytic leukemia or three cases of diffuse, well-differentiated lymphocytic 
lymphoma,  both  of which  represent  neoplastic  proliferation  of medullary  cord  B 
lymphocytes (20).  Among the lymphomas of follicle center cell lineage (20), a single 
case of chronic lymphosarcoma cell leukemia was doubly marked; there were 2 dual 
marker cases among  12 nodular poorly differentiated lymphocytic lymphomas, one 
case among four diffuse, poorly differentiated lymphocytic lymphomas, and  1 case 
among 18 diffuse histiocytic lymphomas. 
Discussion 
Since 1974, when Brouet and Prieur (2) investigated two patients with lymphocytic 
leukemia, whose neoplastic cells bore surface immunoglobulin and  formed rosettes 
with  sheep  erythrocytes, there  have  been  numerous  reports  (3-10)  of malignant 
lymphocytes bearing both  B  and  T  cell surface markers.  These dual  cases can  be 
placed  in  several  categories.  One  group  consists  of patients  with  lymphoblastic 
lymphoma, childhood acute lymphocytic leukemia, and T  cell chronic lymphocytic 
leukemia, whose malignant cells were both E-rosette positive and positive for comple- 
ment receptors (5, 6). Such cases appear to represent proliferations of T  lymphocytes 
bearing complement receptors; these cells closely resemble immature thymocytes with 
similar markers that are present during the  10th to the  15th wk of gestation  (21).  A 
second group consists of patients whose neoplastic cells bear clonal surface immuno- T
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globulin  and  are  reactive with  anti-T  cell  antisera  (8-10).  These  cases  are  more 
difficult to explain, to some extent because of the differing and incompletely defined 
specificities of anti-T cell antisera. 
The  final  category of dual  marker case  are  patients  whose neoplastic cells bear 
clonal surface immunoglobulin and are E-rosette positive. One of the early patients 
of Brouet and  Prieur  (2)  falls into this category; subsequently,  additional  patients 
have been described with similar cell surface markers (3, 4,  7). Several investigators 
ascribed these cases to anti-sheep erythrocyte activity of the membrane-bound IgM 
antibody of  otherwise unexceptional B cells. The evidence for this hypothesis appeared 
convincing;  it  included  the  finding that  protease treatment  of the  neoplastic cells 
abolished rosette formation, that  treatment with  appropriate anti-immunoglobulin 
heavy  and  light  chain  antisera  interfered with  rosette  formation,  and  that  these 
neoplastic cells formed rosettes at elevated temperatures, whereas, normally, reduced 
temperatures favor rosette formation (2, 7). However, it should be noted that E-rosette 
formation of normal T  cells is also abrogated by protease treatment  (22), and  that 
similar  abnormal  temperature  dependence  of rosette  formation  was  observed  in 
otherwise typical malignant and nonmalignant T  cells (23), and also that one group 
of investigators was unable to interfere with rosette formation of doubly marked cells 
by treatment with either anti-immunoglobulin antiserum  or by induced polar cap 
migration of the surface IgM (4). Thus, the anti-sheep erythrocyte activity of surface 
IgM of neoplastic cells might not explain all such dual marker cases. 
In the cases reported here, the B cell membrane characteristic was established by 
the  demonstration  of surface-bound  immunoglobulin  that  was  clonal  both  with 
respect to the IgM heavy chain and the ~ light chain. Furthermore, the presence of 
Ia-like antigen and complement receptors on the neoplastic cells is consistent with a 
B cell lineage, although the latter characteristics are not restricted to B lymphocytes 
(19). The present investigation extends the characterization of these doubly marked 
cases through the use of monoclonal anti-T cell antibodies. In each of the five cases, 
the neoplastic lymphocytes reacted with a monoclonal antibody that detects the sheep 
erythrocyte receptor; all but one reacted with a monoclonal antibody directed against 
a  determinant present on normal peripheral blood T  cells, and all but one reacted 
with a  monoelonal antibody specific for either the inducer/helper or the cytotoxic/ 
suppressor T cell subsets. In addition, lymphocytes from two of the five were E-rosette 
positive. The combined evidence strongly suggests that the neoplastic lymphocytes of 
our patients exhibit both B and T  surface membrane characteristics. 
A  number  of mechanisms  have  been  proposed  for  the  presence  of B  and  T 
determinants on the same cell: derepression of genetic material as a result of neoplastic 
transformation  (3), transformation of a  stem cell before divergence of the B  and T 
lymphocyte pathways  (4), and neoplastic expansion of a  population of normal cells 
that  express  both  markers  (8).  The  evidence does  not  permit  a  confident  choice 
between these alternatives, nor are these mechanisms mutually exclusive. 
Our findings suggest that cases with double marker cells share two characteristics: 
(a) variability in expression of T  cell surface antigens on the neoplastic cells and (b) 
the tendency for the neoplastic cells to be of follicle center B cell lineage. One example 
of  the  variability  of T  cell  surface  properties  is  the  varying  avidity  for  sheep 
erythrocytes; the avidity ranges from high (binding oferythrocytes occurring at 37°C) 
(2) to normal (binding occurring at 4°C but not at 37°C), as in our first two cases, to AISENBERG  ET  AL.  BRIEF  DEFINITIVE  REPORT  1713 
nonexistent  (no binding  at  4°C  or  37°C  despite  evidence for the  presence of the 
erythrocyte receptor  antigen  on  the  neoplastic  cells),  as  in  our  last  three  cases. 
Similarly, we observed cases whose neoplastic cells bore surface determinants of the 
cytotoxic/suppressor T  cell subset or of the inducer/helper subset or of neither subset. 
A  second shared characteristics  of the  dual  marker cases relates  to their follicle 
center lineage  (20).  This B  lymphocyte line is characterized by elefted nuclei and 
abundant surface-associated immunoglobulin (16, 20). A disproportionate number of 
the previously reported cases (2-4, 7) with double marker cells (four of six) were from 
nodular,  poorly  diffentiated  lymphocytic lymphoma  or  its  leukemic  counterpart, 
chronic  lymphosarcoma  cell  leukemia.  Both  of these  diseases  involve  neoplastic 
proliferation of B lymphocytes of the follicle center (20). All five of our cases were of 
follicle center B cell lineage. 
Thus, the dual marker eases might represent neoplastic transformations of a follicle 
center B lymphocyte; such transformation might be accompanied by the expression 
of genes that  regulate T  cell antigens.  The restriction of this expression to cells of 
follicle center lineage  suggests  that  derepression  is  not  random  but  is  directed or 
limited by the degree of differentiation of the transformed cell. Finally, it might be 
considered  that  double-marker  cases  represent  neoplastic  proliferation  of normal 
lymphocytes bearing dual markers; such cells have been detected among peripheral 
blood mononuclear cells (24). Perhaps these cells normally reside in lymphoid follicles; 
the cells reported by Poppema et al.  (25)  located at  the periphery of the germinal 
center in secondary follicles might be candidates for examination for the presence of 
dual markers. 
Summary 
In  the  course  of analyzing  human  lymphoma  tissue  with  conventional surface 
marker techniques and with monoclonal antibodies directed against  T  cell subsets, 
five tumors were encountered with dual B and T  cell determinants. All bore on their 
surface membrane IgM of i¢ light chain type, complement receptors, and the Ia-like 
antigen. In each of the five cases, the neoplastic lymphocytes reacted with a  mono- 
clonal  antibody that  detects the  sheep erythrocyte receptor (OKTll);  all  but  one 
reacted with a  monoclonal antibody for peripheral T  cells (OKT3); and all but one 
reacted with a monoclonal antibody specific for either the inducer-helper (OKT4) or 
the cytotoxic-suppressor (OKT8) T  cell subsets. In addition, lymphocytes from two of 
the five cases formed spontaneous rosettes with sheep erythrocytes (E-rosettes). These 
tumors with dual B and T  surface characteristics were confined to human malignant 
lymphomas that originate from B lymphocytes of the follicle center. 
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